Evidence map›Paper›PMID 29915537›Full record

ReviewFrontiers in pharmacology2018

Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening.

Aliesha Griffin, Kyla R Hamling, SoonGweon Hong, Mana Anvar, Luke P Lee, Scott C Baraban

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. New epilepsy therapies in development.Nature reviews. Drug discovery · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Aliesha GriffinEpilepsy Research Laboratory Department of Neurological Surgery and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.
Kyla R HamlingEpilepsy Research Laboratory Department of Neurological Surgery and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.
SoonGweon HongDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, United States.
Mana AnvarEpilepsy Research Laboratory Department of Neurological Surgery and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.
Luke P LeeDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, United States.
Scott C BarabanEpilepsy Research Laboratory Department of Neurological Surgery and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.
Neurological Surgery · USUniversity of California, Berkeley · USUniversity of California, San Francisco · US

Funding

ZEBRAFISH MODELS FOR DRAVET SYNDROME RESEARCH AND DISCOVERYR01NS096976 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARABAN, SCOTT C · 2016 to 2024
$3.9M
Functional evaluation of catastrophic childhood epilepsy genes in zebrafishR01NS103139 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARABAN, SCOTT C · 2017 to 2020
$1.4M
Using Zebrafish to Advance our Understanding and Treatment of EpilepsyR01NS079214 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARABAN, SCOTT C · 2012 to 2015
$1.2M
NINDS NIH HHS R01 NS079214NINDS NIH HHS R01 NS096976NINDS NIH HHS R01 NS103139
6 · The paper itself

Abstract

Epilepsy is a common chronic neurological disease affecting almost 3 million people in the United States and 50 million people worldwide. Despite availability of more than two dozen FDA-approved anti-epileptic drugs (AEDs), one-third of patients fail to receive adequate seizure control. Specifically, pediatric genetic epilepsies are often the most severe, debilitating and pharmaco-resistant forms of epilepsy. Epileptic syndromes share a common symptom of unprovoked seizures. While some epilepsies/forms of epilepsy are the result of acquired insults such as head trauma, febrile seizure, or viral infection, others have a genetic basis. The discovery of epilepsy associated genes suggests varied underlying pathologies and opens the door for development of new "personalized" treatment options for each genetic epilepsy. Among these, Dravet syndrome (DS) has received substantial attention for both the pre-clinical and early clinical development of novel therapeutics. Despite these advances, there is no FDA-approved treatment for DS. Over 80% of patients diagnosed with DS carry a

Indexed as

animal modelsantiepileptic drugsdravet syndromedrug discoveryepilepsyin vivoprecision medicine

Identifiers

PMID29915537
PMCPMC5994396
OpenAlexW2807232570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.